Mylan
Pfizer to pay $345 million in EpiPen lawsuit
July 16, 2021Medical Communications Mylan, Pfizer, epipen
Pfizer has reached a $345 million settlement over consumer claims they overpaid for EpiPens as a result of unfair, anticompetitive …
Mylan reaches agreement with Aspen for their European thrombosis business
September 8, 2020Manufacturing and Production Mylan, aspen
Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s thrombosis business for €641.9 million. …
Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute
August 20, 2020Sales and Marketing Biogen, FDA, Mylan, generic, tecfidera
The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding authorisation to Mylan which is …
Mylan launches generic version of Gilead’s remdesivir for COVID-19 patients in India
July 20, 2020Sales and Marketing COVID-19, Gilead, India, Mylan, generic, remdesivir
Mylan has launched its own generic version of Gilead’s remdesivir on the Indian market for the treatment of patients with …
Biogen stock surges following patent victory over Mylan for Tecfidera
February 6, 2020Sales and Marketing Biogen, Mylan, multiple sclerosis, pharma, tecfidera
Biogen has emerged victorious in a patent dispute with Mylan relating to the latter’s multiple sclerosis therapy Tecfidera – a …
Mylan and Upjohn merger will create a new entity: Viatris
November 13, 2019Manufacturing and Production, Research and Development, Sales and Marketing Mylan, Pfizer, Upjohn, Viatris, pharma
The name for the new company emerging out of the merger between Pharma firm Mylan and Pfizer division Upjohn has …
Mylan issues recall for anxiety drug Xanax over contamination fears
October 29, 2019Manufacturing and Production Mylan, anxiety, pharma, xanax
Mylan has announced it has issued a recall of its anxiety therapy Xanax (alprazolam) over suspicions the drug could be …
Top Ten most popular articles on Pharmafile.com this week
September 6, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Mylan, brexit
It’s Friday, meaning the weekend is within reach and it’s time for a rundown of the most popular articles on …
Mylan gets provisional FDA greenlight for generic version of Lilly’s blockbuster cancer drug Alimta
September 2, 2019Sales and Marketing Alimta, Cancer, Eli Lilly, FDA, Mylan, pharma
Mylan has scored a preliminary approval in the US from the FDA for its generic version of Eli Lilly’s blockbuster …
Teva launch generic version of EpiPen for children
August 21, 2019Research and Development Mylan, Teva, allergies, children, epipen, pharma
A generic version of Mylan’s EpiPen, manufactured by Teva, is now available for children weighing between 15kg and 30kg in …
Pfizer to combine off-patent drug unit Upjohn with Mylan
July 30, 2019Manufacturing and Production M&A, MA, Mylan, Pfizer, Upjohn, biosimilars, generics, mergers
Pfizer’s off-patent drug unit Upjohn is combining with Mylan to create a new global pharmaceutical company focused on the low-price …
Novartis aims to solve EpiPen shortage with generic launch of Symjepi to US pharmacies
July 10, 2019Manufacturing and Production, Research and Development, Sales and Marketing Mylan, Novartis, Sandoz, US, epipen, pharma
Novartis has announced the immediate availability of its generic epinephrine auto-injector in pharmacies throughout the US, as it moves to …
Generics firms investigated for their involvement in the ‘largest cartel in the history of the United States’
December 11, 2018Manufacturing and Production Dr Reddy's, Mylan, Teva, US, corruption, generics, price fixing, price-fixing, sun
At least 16 generic drugmakers are being investigated for their involvement in what has been described as the “largest cartel …
Teva’s EpiPen generic retails for same price as Mylan’s own
November 28, 2018Research and Development, Sales and Marketing Mylan, Teva, epipen, pharma
Israeli generics firm Teva has revealed the price tag of its generic version of Mylan’s EpiPen epinephrine auto-injector, and, at …
NHS to save £300 million by switching to Humira biosimilars
November 27, 2018Manufacturing and Production, Sales and Marketing AbbVie, Humira, Mylan, NHS, Sandoz, adalimumab, biosimilars, pharrma
NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
